The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Oncolytic virus therapy: A new era of cancer treatment at dawn
Open accessAbstract
Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success in immunotherapy using immune checkpoint inhibitors. Oncolytic viruses are defined as genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming the normal tissues. T‐Vec (talimogene laherparepvec), a second‐generation oncolytic herpes simplex virus type 1 (HSV‐1) armed with GM‐CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. The phase III trial proved that local intralesional injections with T‐Vec in advanced malignant melanoma patients can not only suppress the growth of injected tumors but also act systemically and prolong overall survival. Other oncolytic viruses that are closing in on drug approval in North America and Europe include vaccinia virus JX‐594 (pexastimogene devacirepvec) for hepatocellular carcinoma, GM‐CSF‐expressing adenovirus CG 0070 for bladder cancer, and Reolysin (pelareorep), a wild‐type variant of reovirus, for head and neck cancer. In Japan, a phase II clinical trial of G47∆, a third‐generation oncolytic HSV‐1, is ongoing in glioblastoma patients. G47∆ was recently designated as a “Sakigake” breakthrough therapy drug in Japan. This new system by the Japanese government should provide G47∆ with priority reviews and a fast‐track drug approval by the regulatory authorities. Whereas numerous oncolytic viruses have been subjected to clinical trials, the common feature that is expected to play a major role in prolonging the survival of cancer patients is an induction of specific antitumor immunity in the course of tumor‐specific viral replication. It appears that it will not be long before oncolytic virus therapy becomes a standard therapeutic option for all cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
A viral inhibitor of peptide transporters for antigen presentation
Früh, K., Ahn, K., Djaballah, H., Sempé, P., van Endert, P. M., Tampé, R., Peterson, P. A., & Yang, Y. (1995) · Nature · doi:10.1038/375415a0 · Cited by 602
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
York, I. A., Roop, C., Andrews, D. W., Riddell, S. R., Graham, F. L., & Johnson, D. C. (1994) · Cell · doi:10.1016/0092-8674(94)90215-1 · Cited by 559
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101136398 · Cited by 465
Self-citationTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Chou, J., & Roizman, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3266 · Cited by 393
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Russell, S. J., Federspiel, M. J., Peng, K.-W., Tong, C., Dingli, D., Morice, W. G., Lowe, V., O'Connor, M. K., Kyle, R. A., Leung, N., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.003 · Cited by 274
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242
Xia, Z.-J., Chang, J.-H., Zhang, L., et al. (2004) · PubMed · Cited by 241
Poppers, J., Mulvey, M., Khoo, D., & Mohr, I. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11215-11221.2000 · Cited by 223
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., Martuza, R. L., & Rabkin, S. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307935110 · Cited by 221
Goldsmith, K., Chen, W., Johnson, D. C., & Hendricks, R. L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.341 · Cited by 206
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Adair, R. A., Roulstone, V., Scott, K. J., Morgan, R., Nuovo, G. J., Fuller, M., Beirne, D., West, E. J., Jennings, V. A., Rose, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003578 · Cited by 192
Norman, K. L., Hirasawa, K., Yang, A.-D., Shields, M. A., & Lee, P. W. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404310101 · Cited by 189
Karapanagiotou, E. M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M. E., Larkin, J., Syrigos, K. N., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2181 · Cited by 189
Rajani, K., Parrish, C., Kottke, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K. G., Diaz, R.-M., Pandha, H., Harrington, K., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.156 · Cited by 182
Systemic reovirus therapy of metastatic cancer in immune-competent mice.
Hirasawa, K., Nishikawa, S. G., Norman, K. L., Coffey, M. C., Thompson, B., Yoon, C., Waisman, D. M., & Lee, P. W. K. (2003) · PubMed · Cited by 173
Galanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 168
The preferential cytotoxicity of reovirus for certain transformed cell lines
Hashiro, G., Loh, P. C., & Yau, J. T. (1977) · Archives of Virology · doi:10.1007/bf01314776 · Cited by 162
Kicielinski, K. P., Chiocca, E. A., Yu, J. S., Gill, G. M., Coffey, M., & Markert, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.21 · Cited by 158
Gollamudi, R., Ghalib, M. H., Desai, K. K., Chaudhary, I., Wong, B., Einstein, M. H., Coffey, M. C., Gill, G. M., Mettinger, K. L., Mariadason, J. M., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9279-8 · Cited by 152
White, C. L., Twigger, K. R., Vidal, L., Bono, J. S. D., Coffey, M. C., Heinemann, L., Morgan, R. B., Merrick, A. E., Errington‐Mais, F., Vile, R. G., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.21 · Cited by 151
Differential sensitivity of normal and transformed human cells to reovirus infection
Duncan, M. R., Stanish, S. M., & Cox, D. C. (1978) · Journal of Virology · doi:10.1128/jvi.28.2.444-449.1978 · Cited by 145
He, B., Chou, J., Brandimarti, R., Mohr, I., Gluzman, Y., & Roizman, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.6049-6054.1997 · Cited by 142
Going viral: a review of replication-selective oncolytic adenoviruses
Larson, C., Oronsky, B. T., Scicinski, J. J., Fanger, G. R., Stirn, M., Oronsky, A. L., & Reid, T. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5116 · Cited by 140
Gong, J., Sachdev, E., Mita, A. C., & Mita, M. M. (2016) · World Journal of Methodology · doi:10.5662/wjm.v6.i1.25 · Cited by 138
Harrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 134
Varghese, S., Rabkin, S. D., Liu, R., Nielsen, P., Ipe, T. S., & Martuza, R. L. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700900 · Cited by 110
Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R. L., & Todo, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2534 · Cited by 103
Self-citationA Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Sborov, D. W., Nuovo, G. J., Stiff, A. R., Mace, T. A., Lesinski, G. B., Benson, D. M., Efebera, Y. A., Rosko, A. E., Pichiorri, F., Grever, M. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1404 · Cited by 102
Ino, Y., Saeki, Y., Fukuhara, H., & Todo, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1494 · Cited by 102
Self-citationOncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
Thirukkumaran, C. M., Nodwell, M. J., Hirasawa, K., Shi, Z.-Q., Diaz, R., Luider, J. M., Johnston, R. N., Forsyth, P. A., Magliocco, A. M., Lee, P. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2408 · Cited by 96
Aghi, M. K., Visted, T., DePinho, R. A., & Chiocca, E. A. (2008) · Oncogene · doi:10.1038/onc.2008.53 · Cited by 94
Oncolytic HSV Armed with Platelet Factor 4, an Antiangiogenic Agent, Shows Enhanced Efficacy
Liu, T., Zhang, T., Fukuhara, H., Kuroda, T., Todo, T., Martuza, R. L., Rabkin, S. D., & Kurtz, A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.011 · Cited by 82
Self-citationOncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Kaur, B., Chiocca, E. A., & Cripe, T. P. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958814 · Cited by 72
Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brain
Liu, R., Martuza, R. L., & Rabkin, S. D. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302445 · Cited by 68
Coffin, R. S. (2016) · Immunotherapy · doi:10.2217/imt.15.116 · Cited by 62
Tsuji, T., Nakamori, M., Iwahashi, M., Nakamura, M., Ojima, T., Iida, T., Katsuda, M., Hayata, K., Ino, Y., Todo, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27681 · Cited by 51
Self-citationPuzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Ai, L., Chou, J., & Kaufman, H. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9063 · Cited by 46
Hoffmann, D., Bangen, J.-M., Bayer, W., & Wildner, O. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302806 · Cited by 42
Oncolytic herpes simplex virus engineering and preparation
Agarwalla, P. K., & Aghi, M. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-340-0_1 · Cited by 37
Cell cycle-regulated transcription in mammalian cells
Zwicker, J., & Müller, R. (1995) · Springer eBooks · doi:10.1007/978-1-4615-1809-9_7 · Cited by 32
Oncolytic HSV-1 for the treatment of brain tumours.
Markert, J. M., Jn, P., Buchsbaum, D. J., Grizzle, W. E., Gillespie, G. Y., & Whitley, R. J. (2006) · PubMed · Cited by 30
Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus
Wang, J., Xu, L., Zeng, W., Hu, P., Rabkin, S. D., & Liu, R.-R. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.3.1241 · Cited by 20
Mita, A. C., Argiris, A. E., Coffey, M. C., Gill, G. M., & Mita, M. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-c70 · Cited by 14
CLINICAL DEVELOPMENT OF A THIRD-GENERATION ONCOLYTIC HSV-1 (G47Δ) FOR MALIGNANT GLIOMA
Ino, Y., & Todo, T. (2010) · Gene Therapy and Regulation · doi:10.1142/s1568558610000185 · Cited by 10
Self-citation
Cited by
Kubes, P., & Jenne, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052415 · Cited by 923
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Therapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Self-citationOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Metadata
- Authors
- Fukuhara, H., Ino, Y., & Todo, T.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2016-09-09
- Volume
- 107
- Issue
- 10
- Pages
- 1373-1379
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2497822529
- Cited by
- 774
- References
- 62
- FWCI
- 43.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.